Early-Stage trial tests re-engineered immune cells against tough prostate cancers
NCT ID NCT02744287
Summary
This early-stage study tested whether a patient's own immune cells could be modified in a lab to recognize and attack advanced prostate cancer. The treatment, called BPX-601, involved collecting a patient's T-cells, engineering them to target a specific marker on cancer cells, and then infusing them back into the patient. The main goals were to check if this approach was safe and to find the right dose, but the study was stopped before moving to the next phase.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor Sammons Cancer Center
Dallas, Texas, 75246, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Duke University
Durham, North Carolina, 27705, United States
-
Emory Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
John Theurer Cancer Center, Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
University of Chicago Medicine
Chicago, Illinois, 60637, United States
-
University of Nebraska
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.